Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuxe, K.
Right arrow Articles by Ferré, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuxe, K.
Right arrow Articles by Ferré, S.
NEUROLOGY 2003;61:S19-S23
© 2003 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Receptor heteromerization in adenosine A2A receptor signaling

Relevance for striatal function and Parkinson’s disease

K. Fuxe, MD PhD, L.F. Agnati, MD PhD, K. Jacobsen, J. Hillion, PhD, M. Canals, BSc, M. Torvinen, PhD, B. Tinner-Staines, W. Staines, PhD, D. Rosin, PhD, A. Terasmaa, MSc, P. Popoli, MD, G. Leo, PhD, V. Vergoni, PhD, C. Lluis, PhD, F. Ciruela, PhD, R. Franco, PhD and S. Ferré, MD PhD

From the Department of Neuroscience (Drs. Fuxe, Torvinen, and Terasmaa), Karolinska Institute, Stockholm, Sweden; Biomedical Sciences (Drs. Agnati, Leo, and Vergoni), University of Modena, Italy; Department of Anatomy (Dr. Staines, K. Jacobsen and B. Tinner-Staines), University of Ottawa, Canada; Stroke Branch (Dr. Hillion), NINDS, NIH, Bethesda, MD; Department of Biochemistry and Molecular Biology (Drs. Lluis, Ciruela, and Franco, M. Canals), University of Barcelona, Spain; Department of Pharmacology (Dr. Rosin), University of Virginia Health Sciences Center, Charlottesville, VA; Department of Pharmacology (Dr. Popoli), Istituto Superiore di Sanita, Rome, Italy; and Pre-clinical Pharmacology Section (Dr. Ferré), Behavioral Neuroscience Branch, NIDA, NIH, IRP, Baltimore, MD.

Address correspondence and reprint requests to Dr. Kjell Fuxe, Department of Neuroscience, Karolinska Institutet, Retzius väg 8, A2:4, S17177, Stockholm, Sweden; e-mail: kjell.fuxe{at}neuro.ki.se

Recently evidence has been presented that adenosine A2A and dopamine D2 receptors form functional heteromeric receptor complexes as demonstrated in human neuroblastoma cells and mouse fibroblast Ltk- cells. These A2A/D2 heteromeric receptor complexes undergo coaggregation, cointernalization, and codesensitization on D2 or A2A receptor agonist treatments and especially after combined agonist treatment. It is hypothesized that the A2A/D2 receptor heteromer represents the molecular basis for the antagonistic A2A/D2 receptor interactions demonstrated at the biochemical and behavioral levels. Functional heteromeric complexes between A2A and metabotropic glutamate 5 receptors (mGluR5) have also recently been demonstrated in HEK-293 cells and rat striatal membrane preparations. The A2A/mGluR5 receptor heteromer may account for the synergism found after combined agonist treatments demonstrated in different in vitro and in vivo models. D2, A2A, and mGluR5 receptors are found together in the dendritic spines of the striatopallidal GABA neurons. Therefore, possible D2/A2A/mGluR5 multimeric receptor complexes and the receptor interactions within them may have a major role in controlling the dorsal and ventral striatopallidal GABA neurons involved in Parkinson’s disease and in schizophrenia and drug addiction, respectively.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
A. Kachroo, L. R. Orlando, D. K. Grandy, J.-F. Chen, A. B. Young, and M. A. Schwarzschild
Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice
J. Neurosci., November 9, 2005; 25(45): 10414 - 10419.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. S. Cowen, E. Djouma, and A. J. Lawrence
The Metabotropic Glutamate 5 Receptor Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine Reduces Ethanol Self-Administration in Multiple Strains of Alcohol-Preferring Rats and Regulates Olfactory Glutamatergic Systems
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 590 - 600.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Torvinen, D. Marcellino, M. Canals, L. F. Agnati, C. Lluis, R. Franco, and K. Fuxe
Adenosine A2A Receptor and Dopamine D3 Receptor Interactions: Evidence of Functional A2A/D3 Heteromeric Complexes
Mol. Pharmacol., February 1, 2005; 67(2): 400 - 407.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. L. Rosin, B. D. Hettinger, A. Lee, and J. Linden
Anatomy of adenosine A2A receptors in brain: Morphological substrates for integration of striatal function
Neurology, December 9, 2003; 61(90116): S12 - 18.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.